Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02703272
Title A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Janssen Research & Development, LLC

non-Hodgkin lymphoma



Carboplatin + Dexamethasone + Etoposide + Ifosfamide + Rituximab

Carboplatin + Dexamethasone + Idarubicin + Ifosfamide + Rituximab + Vincristine Sulfate

Age Groups: child | adult
Covered Countries USA | FRA | ESP | DEU | CAN | BEL

No variant requirements are available.